Louis Chorich, MD
Retina Specialist · Dublin, OHNPI 1487698288
Payments from drug & device makers
What this record shows
This record is dominated by ownership interests: $33,223 of the $40,406 with a category attached, or 82.2%. US Retina LLC accounts for 89.5% of it on its own, with 23 other manufacturers making up the rest. Reporting peaked in 2022 at $14,556 and has fallen 95.6% since, to $642 in 2025.
Across 130 payments — averaging $310.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- US Retina LLC$36K
- Mallinckrodt Hospital Products Inc.$559
- Genentech USA, Inc.$458
- Apellis Pharmaceuticals, Inc.$431
- Novartis$404
- Alimera Sciences, Inc.$340
- plus $2K from 18 others
What the payments were for
- Food & beverage$4,13410%
- Education$1020%
- Ownership interest$33,22382%
- Other$2,9487%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| US Retina LLC | 11 | $36,170 |
| Mallinckrodt Hospital Products Inc. | 13 | $559 |
| Genentech USA, Inc. | 17 | $458 |
| Apellis Pharmaceuticals, Inc. | 10 | $431 |
| Novartis | 9 | $404 |
| Alimera Sciences, Inc. | 13 | $340 |
| AbbVie(2 entities) | 11 | $338 |
| Regeneron Healthcare Solutions, Inc. | 8 | $324 |
| Astellas Pharma US Inc | 6 | $296 |
| Dutch Ophthalmic, USA | 1 | $177 |
| Amgen | 4 | $167 |
| Alcon | 2 | $131 |
| Regeneron | 1 | $110 |
| Eyepoint US, Inc. | 5 | $98 |
| Genentech, Inc. | 1 | $79 |
| Biogen | 4 | $65 |
| ANI Pharmaceuticals, Inc. | 2 | $58 |
| Coherus Oncology, Inc. | 3 | $48 |
| Sandoz | 2 | $45 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 2 | $39 |
| Spark Therapeutics, Inc. | 2 | $25 |
| Mallinckrodt Enterprises LLC | 1 | $19 |
| Sight Sciences, Inc. | 1 | $15 |
| Halozyme Inc | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$40,406 in reported general payments places this provider in the 80th percentile of 69 retina specialist providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 119 | $3,239 |
| Difluprednate | 31 | $2,908 |
| Atropine Sulfate | 58 | $1,635 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 35 | $745 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 81 | $723 |
| Timolol Maleate | 40 | $235 |
| Ketorolac Tromethamine | 18 | $222 |
| Latanoprost | 23 | $196 |
| Brimonidine Tartrate | 29 | $139 |
| Dorzolamide Hcl | 16 | $121 |
| Prednisone | 16 | $51 |
Paid to pharmacies, not to this prescriber.
Other retina specialist in Dublin
- Sugat PatelDublin$33K
- Dino KlisovicDublin$21K
- Dominic BuzzaccoDublin$12K
- Vishal ParikhDublin$11K
- Johnstone KimDublin$10K
- Joseph ConeyBeachwood$980K
- Sumit SharmaCleveland$428K
- Aleksandra RachitskayaCleveland$303K
- David MillerBeachwood$299K
- Katherine TalcottCleveland$272K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.